For six years, Tukysa (tucatinib) was a drug doctors turned to after other treatments had stopped working. On October 7, the FDA moved it much earlier. The agency approved tucatinib, combined with trastuzumab and pertuzumab, as maintenance therapy for adults with unresectable locally advanced or metastatic HER2-positive breast cancer, following induction treatment.
Pfizer calls the regimen chemotherapy-free. Chemo isn't skipped, though. In the trial behind the approval, every patient first received trastuzumab, pertuzumab and a taxane, and only those whose disease hadn't progressed went on to maintenance. The change is what comes after: the two antibodies plus an oral HER2 inhibitor, instead of the antibodies alone.
Tukysa keeps its earlier indication, too: with trastuzumab and capecitabine for advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, after one or more prior anti-HER2 treatments in the metastatic setting.
The Trial: HER2CLIMB-05 #
HER2CLIMB-05 was a randomized, double-blind, placebo-controlled Phase 3 study in 654 patients: 326 on tucatinib plus trastuzumab and pertuzumab, 328 on placebo plus the same two antibodies. The primary endpoint was investigator-assessed progression-free survival (PFS), and overall survival is a key secondary endpoint. The data were presented at SABCS 2025 and published in the Journal of Clinical Oncology.
Median PFS was 24.9 months with tucatinib (95% CI 21.3 to not reached) and 16.3 months with placebo (95% CI 12.6 to 18.7). That's 8.6 months longer, and the risk of progression or death fell by 35.9% (HR 0.64; 95% CI 0.51-0.80; p<0.0001).
The Liver: Boxed Warning for Severe Hepatotoxicity #
The label carries a boxed warning for severe hepatotoxicity. Pfizer's safety information says Tukysa can cause severe and fatal liver toxicity, particularly after rechallenge. Pfizer also says most liver events were asymptomatic and reversible with dose changes or discontinuation, and that the rest of the safety profile matched what was already known. In HER2CLIMB-05:
| Measure (tucatinib arm) | Result |
|---|---|
| ALT above 5 × ULN | 18% |
| AST above 5 × ULN | 10% |
| Bilirubin above 3 × ULN (Grade ≥3) | 1.2% |
| Serious hepatotoxicity | 3.9% |
| Confirmed Hy's Law cases | 5, including one fatal (all after rechallenge) |
One patient died of drug-induced liver injury. Overall, 14% permanently stopped Tukysa (8% for hepatotoxicity), 49% had a dose interruption and 29% had a dose reduction. Serious adverse reactions of any kind occurred in 17%.
Monitoring is demanding at the start. The label calls for ALT, AST and bilirubin tests before treatment, every 2 weeks for the first 2 months, then every 3 weeks, and whenever clinically needed. If treatment restarts after liver problems clear, testing goes weekly.
Diarrhea and Other Effects #
Diarrhea affected 73% of patients on tucatinib, and 6% had Grade 3. It usually began around day 11 and resolved in about 2 days. The trial did not require preventive antidiarrheal medicine. The other common adverse reactions (20% or more) were musculoskeletal pain, hepatotoxicity, nausea, fatigue, rash and vomiting.
Tukysa can also raise serum creatinine by roughly 29-32% in the first 21 days without damaging the kidneys, so doctors should judge kidney function by other measures. It can harm a fetus, and contraception is advised during treatment and for a week after the last dose.
What's Missing: Overall Survival #
Overall survival is a key secondary endpoint, and Pfizer's own release lists it as an open uncertainty. The control arm was placebo plus the two antibodies, so the trial says nothing about tucatinib versus other maintenance approaches. And everyone enrolled had finished induction without progressing, so the result doesn't cover people whose disease advanced earlier.
An 8.6-month gain in progression-free time is large for patients who responded well to induction. Whether it translates into longer survival is the number that will decide how widely this regimen is used, and it hasn't been reported yet.
Quick terms: HER2-positive means tumor cells make too much HER2 protein (Pfizer cites up to 15-20% of breast cancers). Maintenance is treatment continued after induction to hold the disease in check. ULN is the upper limit of normal for a lab value.
(Related Bench Protocol: HER2 IHC and Antigen Retrieval Optimization | Liquid Biopsy ctDNA Assay Validation)
For information only, not medical advice. Sources: Pfizer press release (Oct 7, 2026); HER2CLIMB-05, Journal of Clinical Oncology; Pfizer's Important Safety Information for Tukysa.
